Join Our 2021 Isotope User Group Meetings
Join Our 2021 Isotope User Group Meetings
Join Our 2021 Isotope User Group Meetings!
In 2021 the DOE Isotope Program will host four virtual user group meetings focused on the following emerging alpha and beta emitters:
actinium-225, astatine-211, lead-212, and new this year, copper-67.
The purpose of the meetings is to encourage free discussion and collaboration amongst users of specific isotopes and accelerate their widespread use in medicine.
These webinar-style sessions will feature brief presentations by leading researchers showcasing their latest progress in these emerging fields, followed by interactive panel discussions. Participants are also encouraged to share insights and ask questions during a moderated Q&A segment.
Actinium-225 User Group Meeting
Join us Tuesday, August 3rd at 1:00 pm ET for our actinium-225 session moderated by Eva Birnbaum from Los Alamos National Laboratory. Presentations from the University of California at Berkeley, the University of Saskatchewan, Weill Cornell, Fusion Pharmaceuticals, and Johns Hopkins University are planned.
Astatine-211 User Group Meeting
Join us Tuesday, August 10th at 1:00 pm ET for our astatine-211 session moderated by Yawen Li from the University of Washington Cyclotron Facility. Presentations from Duke University, Texas A&M University, the University of California at Davis, and the University of Pennsylvania are planned.
Lead-212 User Group Meeting
Join us Tuesday, August 17th at 1:00 pm ET for our lead-212 session moderated by Roy Copping from Oak Ridge National Laboratory. Presentations from Viewpoint Molecular Targeting, the University of California at Berkeley, and Pacific Northwest National Laboratory are planned.
Copper-67 User Group Meeting
Join us Tuesday, August 24th at 1:00 pm ET for our copper-67 session moderated by Dave Rotsch from Argonne National Laboratory. Presentations from City of Hope National Medical Center, Boston Children's Hospital, Hunter College, the University of Alabama at Birmingham, and Clarity Pharmaceuticals are planned.
